MBX Biosciences, Inc. Common Stock
NASDAQ:MBXBiotechnology
-$0.64 today
- Market cap
- $2.65B
- Beta
- 0.75
- P/E (TTM)
- -22.0
- EPS (TTM)
- -$1.86
Volume 0.73M
Average 0.65M
MBX Depreciation & Amortization
Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.
MBX Biosciences, Inc. Common StockNASDAQ: MBX
Depreciation & Amortization · Q3 FY2026 · quarter ended Sep 2026
Depreciation & amortization growth accelerates
Q3 FY2026 depreciation & amortization of $140K rose 180.0% year over year, ahead of the +39.4% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 77.2% from the prior quarter. Over 3 fiscal years it compounded at +64.2% a year.
Context
- Depreciation & amortization increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +180.0% holds above the trailing-twelve-month pace of +39.4%.
Sources:Income StatementText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the income statement
- Latest · FY2025
- 248K USD
- Year-over-year change
- +1.6%
- 3-year CAGR
- +64.2%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 248K | +1.6% |
| FY2024 | 2024-12-31 | 244K | +55.4% |
| FY2023 | 2023-12-31 | 157K | +180.4% |
| FY2022 | 2022-12-31 | 56K | — |
Depreciation & Amortization vs competitors
How MBX compares with its peers on the latest reported figures
- Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +39.4% is the highest of 8, against a peer median of -27.5%.
- Over three fiscal years its annual growth of +64.2% compares with a peer median of -1.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | €18.33M EUR | +5.7% | -1.8% | 1.5% | |
| LTM Mar 2026 | $12.61M USD | +0.4% | -1.4% | 4.0% | |
| LTM Mar 2026 | $1.02M USD | -43.2% | +26.8% | — | |
| LTM Sep 2026 | $775K USD | -46.5% | -7.2% | 0.3% | |
| LTM Jun 2026 | $450K USD | +7.1% | +14.0% | — | |
MBXMBX Biosciences, Inc. Common Stock | LTM Sep 2026 | $343K USD | +39.4% | +64.2% | — |
KLRAKailera Therapeutics, Inc. | FY2025 | $310K USD | — | — | — |
| LTM Mar 2026 | $121K USD | -27.5% | -67.8% | — | |
| LTM Mar 2026 | $106K USD | -33.8% | -39.0% | 294.4% | |
| Peer median (excluding MBX) | — | -27.5% | -1.8% | 2.8% | |
Competitors are the stored peer set for MBX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 248K |
| Gross Profit | 0 | 0 | 0 | (248K) |
| Gross Margin | — | — | — | — |
| Research & Development | 21.4M | 28.53M | 57.42M | 79.16M |
| Selling, General & Admin | 3.76M | 6.78M | 10.78M | 18.9M |
| Operating Expenses | 25.16M | 35.31M | 68.19M | 98.06M |
| Depreciation & Amortization | 56K | 157K | 244K | 248K |
| EBITDA | (25.71M) | (32.41M) | (61.68M) | (86.72M) |
| EBITDA Margin | — | — | — | — |
| Operating Income | (25.16M) | (35.31M) | (68.19M) | (98.06M) |
| Operating Margin | — | — | — | — |
| Interest Income | 372K | 2.75M | 6.27M | 11.08M |
| Interest Expense | 374K | 0 | 0 | 0 |
| Other Income / Expenses | (974K) | 2.75M | 6.27M | 11.08M |
| Income Before Tax | (26.14M) | (32.56M) | (61.92M) | (86.97M) |
| Pre-Tax Margin | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 |
| Net Income | (26.14M) | (32.56M) | (61.92M) | (86.97M) |
| Net Margin | — | — | — | — |
| EPS (Basic) | (0.82) | (1.02) | (1.85) | (2.38) |
| EPS (Diluted) | (0.82) | (1.02) | (1.85) | (2.38) |
| Weighted Avg Shares | 31.85M | 31.85M | 33.39M | 36.51M |
| Weighted Avg Shares (Diluted) | 31.85M | 31.85M | 33.39M | 36.51M |
MBX Biosciences, Inc. Common Stock
NASDAQ:MBX
Intrinsic Alpha fair value
Locked
Current Price
$53.42
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.